BiotechTube
Home/Xencor/Mark Osterman, M.D., M.S.C.E.
MO

Mark Osterman, M.D., M.S.C.E.

Senior Vice President, Clinical Development (Autoimmune)

Xencor

Therapeutic Areas

OncologyAutoimmune DisordersInfectious Disease

Xencor Pipeline

DrugIndicationPhase
Vibostolimab (XmAb®23104)Advanced Solid TumorsPhase 2
XmAb®808Advanced Solid TumorsPhase 1
XmAb®541Advanced Solid TumorsPhase 1
XmAb®819Renal Cell CarcinomaPhase 1
XmAb®104Oncology (Combination)Phase 1
Plamotamab (XmAb®13676)B-cell MalignanciesPhase 2
XmAb®14045Acute Myeloid Leukemia (AML)Phase 2
Vunakizumab (XmAb®2513)Autoimmune DiseasesPhase 1

Leadership Team at Xencor

BI
Bassil I. Dahiyat, Ph.D.
President & Chief Executive Officer, Director
JR
John R. Desjarlais, Ph.D.
Executive Vice President, Research & Chief Scientific Officer
DL
Dane Leone
Executive Vice President & Chief Strategy Officer
BC
Bart Cornelissen
Senior Vice President & Chief Financial Officer
CE
Celia Eckert, J.D.
Senior Vice President, General Counsel & Corporate Secretary
EP
Eric P. Kowack
Senior Vice President, Program Leadership & Alliance Management
KR
Kirk Rosemark
Senior Vice President, Regulatory Affairs & Quality Assurance
JS
Jennifer Sandoz
Senior Vice President, Human Resources
View full Xencor profile